#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Changes in Gray Matter Density, Regional Homogeneity, and Functional Connectivity in Methamphetamine-Associated Psychosis: A Resting-State Functional Magnetic Resonance Imaging (fMRI) Study
#Text=Background
#Text=Using regional homogeneity (ReHo) blood oxygen level-dependent functional MR (BOLD-fMRI), we investigated the structural and functional alterations of brain regions among patients with methamphetamine-associated psychosis (MAP).
1-1	0-7	Changes	_	
1-2	8-10	in	_	
1-3	11-15	Gray	_	
1-4	16-22	Matter	_	
1-5	23-30	Density	_	
1-6	30-31	,	_	
1-7	32-40	Regional	_	
1-8	41-52	Homogeneity	_	
1-9	52-53	,	_	
1-10	54-57	and	_	
1-11	58-68	Functional	_	
1-12	69-81	Connectivity	_	
1-13	82-84	in	_	
1-14	85-111	Methamphetamine-Associated	_	
1-15	112-121	Psychosis	_	
1-16	121-122	:	_	
1-17	123-124	A	_	
1-18	125-138	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-19	139-149	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-20	150-158	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-21	159-168	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-22	169-176	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-23	177-178	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-24	178-182	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-25	182-183	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
1-26	184-189	Study	_	
1-27	190-200	Background	_	
1-28	201-206	Using	_	
1-29	207-215	regional	_	
1-30	216-227	homogeneity	_	
1-31	228-229	(	_	
1-32	229-233	ReHo	_	
1-33	233-234	)	_	
1-34	235-240	blood	_	
1-35	241-247	oxygen	_	
1-36	248-263	level-dependent	_	
1-37	264-274	functional	_	
1-38	275-277	MR	_	
1-39	278-279	(	_	
1-40	279-288	BOLD-fMRI	_	
1-41	288-289	)	_	
1-42	289-290	,	_	
1-43	291-293	we	_	
1-44	294-306	investigated	_	
1-45	307-310	the	_	
1-46	311-321	structural	_	
1-47	322-325	and	_	
1-48	326-336	functional	_	
1-49	337-348	alterations	_	
1-50	349-351	of	_	
1-51	352-357	brain	_	
1-52	358-365	regions	_	
1-53	366-371	among	_	
1-54	372-380	patients	_	
1-55	381-385	with	_	
1-56	386-412	methamphetamine-associated	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
1-57	413-422	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[3]	
1-58	423-424	(	_	
1-59	424-427	MAP	_	
1-60	427-428	)	_	
1-61	428-429	.	_	

#Text=Material/Methods
#Text=This retrospective study included 17 MAP patients, 16 schizophrenia (SCZ) patients, and 18 healthy controls.
2-1	430-438	Material	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
2-2	438-439	/	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
2-3	439-446	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
2-4	447-451	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-5	452-465	retrospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-6	466-471	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-7	472-480	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-8	481-483	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-9	484-487	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[6]	
2-10	488-496	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[6]	
2-11	496-497	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-12	498-500	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-13	501-514	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
2-14	515-516	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
2-15	516-519	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
2-16	519-520	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
2-17	521-529	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
2-18	529-530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-19	531-534	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-20	535-537	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
2-21	538-545	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
2-22	546-554	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
2-23	554-555	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	

#Text=Informed consent was obtained from all patients before the clinical assessment, the severity of clinical symptoms was evaluated prior to the fMRI scanning, and then images were acquired and preprocessed after each participant received 6-min fRMI scanning.
3-1	556-564	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-2	565-572	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-3	573-576	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-4	577-585	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-5	586-590	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-6	591-594	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-7	595-603	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-8	604-610	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-9	611-614	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-10	615-623	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-11	624-634	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-12	634-635	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-13	636-639	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-14	640-648	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-15	649-651	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-16	652-660	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-17	661-669	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-18	670-673	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-19	674-683	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-20	684-689	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-21	690-692	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-22	693-696	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-23	697-701	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
3-24	702-710	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-25	710-711	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-26	712-715	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-27	716-720	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-28	721-727	images	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-29	728-732	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-30	733-741	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-31	742-745	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-32	746-758	preprocessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-33	759-764	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-34	765-769	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-35	770-781	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-36	782-790	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-37	791-792	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-38	792-793	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-39	793-796	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
3-40	797-801	fRMI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[10]	
3-41	802-810	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[10]	
3-42	810-811	.	_	

#Text=The participants all underwent BOLD-fMRI scanning.
4-1	812-815	The	_	
4-2	816-828	participants	_	
4-3	829-832	all	_	
4-4	833-842	underwent	_	
4-5	843-852	BOLD-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
4-6	853-861	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
4-7	861-862	.	_	

#Text=Voxel-based morphometry was used to measure gray matter density (GMD).
5-1	863-874	Voxel-based	_	
5-2	875-886	morphometry	_	
5-3	887-890	was	_	
5-4	891-895	used	_	
5-5	896-898	to	_	
5-6	899-906	measure	_	
5-7	907-911	gray	_	
5-8	912-918	matter	_	
5-9	919-926	density	_	
5-10	927-928	(	_	
5-11	928-931	GMD	_	
5-12	931-932	)	_	
5-13	932-933	.	_	

#Text=Resting-state fMRI (rs-fMRI) was conducted to analyze functional MR, ReHo, and functional connectivity (FC).
6-1	934-947	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
6-2	948-952	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
6-3	953-954	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
6-4	954-961	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
6-5	961-962	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
6-6	963-966	was	_	
6-7	967-976	conducted	_	
6-8	977-979	to	_	
6-9	980-987	analyze	_	
6-10	988-998	functional	_	
6-11	999-1001	MR	_	
6-12	1001-1002	,	_	
6-13	1003-1007	ReHo	_	
6-14	1007-1008	,	_	
6-15	1009-1012	and	_	
6-16	1013-1023	functional	_	
6-17	1024-1036	connectivity	_	
6-18	1037-1038	(	_	
6-19	1038-1040	FC	_	
6-20	1040-1041	)	_	
6-21	1041-1042	.	_	

#Text=Results
#Text=GMD analysis results suggest that MAP patients, SCZ patients, and healthy volunteers show different GMDs within different brain regions.
7-1	1043-1050	Results	_	
7-2	1051-1054	GMD	_	
7-3	1055-1063	analysis	_	
7-4	1064-1071	results	_	
7-5	1072-1079	suggest	_	
7-6	1080-1084	that	_	
7-7	1085-1088	MAP	_	
7-8	1089-1097	patients	_	
7-9	1097-1098	,	_	
7-10	1099-1102	SCZ	_	
7-11	1103-1111	patients	_	
7-12	1111-1112	,	_	
7-13	1113-1116	and	_	
7-14	1117-1124	healthy	_	
7-15	1125-1135	volunteers	_	
7-16	1136-1140	show	_	
7-17	1141-1150	different	_	
7-18	1151-1155	GMDs	_	
7-19	1156-1162	within	_	
7-20	1163-1172	different	_	
7-21	1173-1178	brain	_	
7-22	1179-1186	regions	_	
7-23	1186-1187	.	_	

#Text=Similarly, the ReHo analysis results suggest that MAP patients, SCZ patients, and healthy volunteers have different GMDs within different brain regions.
8-1	1188-1197	Similarly	_	
8-2	1197-1198	,	_	
8-3	1199-1202	the	_	
8-4	1203-1207	ReHo	_	
8-5	1208-1216	analysis	_	
8-6	1217-1224	results	_	
8-7	1225-1232	suggest	_	
8-8	1233-1237	that	_	
8-9	1238-1241	MAP	_	
8-10	1242-1250	patients	_	
8-11	1250-1251	,	_	
8-12	1252-1255	SCZ	_	
8-13	1256-1264	patients	_	
8-14	1264-1265	,	_	
8-15	1266-1269	and	_	
8-16	1270-1277	healthy	_	
8-17	1278-1288	volunteers	_	
8-18	1289-1293	have	_	
8-19	1294-1303	different	_	
8-20	1304-1308	GMDs	_	
8-21	1309-1315	within	_	
8-22	1316-1325	different	_	
8-23	1326-1331	brain	_	
8-24	1332-1339	regions	_	
8-25	1339-1340	.	_	

#Text=Negative correlations were found between ReHo- and the PANSS-positive scores within the left orbital interior frontal gyrus (L-orb-IFG) of MAP patients.
9-1	1341-1349	Negative	_	
9-2	1350-1362	correlations	_	
9-3	1363-1367	were	_	
9-4	1368-1373	found	_	
9-5	1374-1381	between	_	
9-6	1382-1386	ReHo	_	
9-7	1386-1387	-	_	
9-8	1388-1391	and	_	
9-9	1392-1395	the	_	
9-10	1396-1410	PANSS-positive	_	
9-11	1411-1417	scores	_	
9-12	1418-1424	within	_	
9-13	1425-1428	the	_	
9-14	1429-1433	left	_	
9-15	1434-1441	orbital	_	
9-16	1442-1450	interior	_	
9-17	1451-1458	frontal	_	
9-18	1459-1464	gyrus	_	
9-19	1465-1466	(	_	
9-20	1466-1475	L-orb-IFG	_	
9-21	1475-1476	)	_	
9-22	1477-1479	of	_	
9-23	1480-1483	MAP	_	
9-24	1484-1492	patients	_	
9-25	1492-1493	.	_	

#Text=ReHo- and PANSS-negative scores of R-SFG were negatively correlated among SCZ patients.
10-1	1494-1498	ReHo	_	
10-2	1498-1499	-	_	
10-3	1500-1503	and	_	
10-4	1504-1518	PANSS-negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
10-5	1519-1525	scores	_	
10-6	1526-1528	of	_	
10-7	1529-1534	R-SFG	_	
10-8	1535-1539	were	_	
10-9	1540-1550	negatively	_	
10-10	1551-1561	correlated	_	
10-11	1562-1567	among	_	
10-12	1568-1571	SCZ	_	
10-13	1572-1580	patients	_	
10-14	1580-1581	.	_	

#Text=The abnormal FC of R-MFG showed a negative correlation with the PANSS score among MAP patients.
11-1	1582-1585	The	_	
11-2	1586-1594	abnormal	_	
11-3	1595-1597	FC	_	
11-4	1598-1600	of	_	
11-5	1601-1606	R-MFG	_	
11-6	1607-1613	showed	_	
11-7	1614-1615	a	_	
11-8	1616-1624	negative	_	
11-9	1625-1636	correlation	_	
11-10	1637-1641	with	_	
11-11	1642-1645	the	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
11-12	1646-1651	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
11-13	1652-1657	score	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[13]	
11-14	1658-1663	among	_	
11-15	1664-1667	MAP	_	
11-16	1668-1676	patients	_	
11-17	1676-1677	.	_	

#Text=Conclusions
#Text=The abnormalities in brain structure and FC were associated with the development of MAP.
12-1	1678-1689	Conclusions	_	
12-2	1690-1693	The	_	
12-3	1694-1707	abnormalities	_	
12-4	1708-1710	in	_	
12-5	1711-1716	brain	_	
12-6	1717-1726	structure	_	
12-7	1727-1730	and	_	
12-8	1731-1733	FC	_	
12-9	1734-1738	were	_	
12-10	1739-1749	associated	_	
12-11	1750-1754	with	_	
12-12	1755-1758	the	_	
12-13	1759-1770	development	_	
12-14	1771-1773	of	_	
12-15	1774-1777	MAP	_	
12-16	1777-1778	.	_	



#Text=Material and Methods
#Text=Participants
#Text=We recruited right-handed men ages 18~45 years, and placed them into 3 groups: MAP (n=19), SCZ (n=19), and control (n=18).
28-1	4074-4082	Material	http://www.case.edu/ProvCaRe/provcare#StudyMethod[14]	
28-2	4083-4086	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[14]	
28-3	4087-4094	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[14]	
28-4	4095-4107	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-5	4108-4110	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-6	4111-4120	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-7	4121-4133	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-8	4134-4137	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-9	4138-4142	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-10	4143-4145	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-11	4145-4146	~	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-12	4146-4148	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-13	4149-4154	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-14	4154-4155	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-15	4156-4159	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-16	4160-4166	placed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-17	4167-4171	them	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-18	4172-4176	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-19	4177-4178	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-20	4179-4185	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-21	4185-4186	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-22	4187-4190	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-23	4191-4192	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-24	4192-4193	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-25	4193-4194	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-26	4194-4196	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-27	4196-4197	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-28	4197-4198	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-29	4199-4202	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-30	4203-4204	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-31	4204-4205	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-32	4205-4206	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-33	4206-4208	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-34	4208-4209	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-35	4209-4210	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-36	4211-4214	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-37	4215-4222	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
28-38	4223-4224	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-39	4224-4225	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-40	4225-4226	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-41	4226-4228	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-42	4228-4229	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
28-43	4229-4230	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=MAP was diagnosed according to the International Classification of Diseases-10 (ICD-10) research criteria.
29-1	4231-4234	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[18]	
29-2	4235-4238	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-3	4239-4248	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-4	4249-4258	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-5	4259-4261	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-6	4262-4265	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-7	4266-4279	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-8	4280-4294	Classification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-9	4295-4297	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-10	4298-4306	Diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-11	4306-4307	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-12	4307-4309	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-13	4310-4311	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-14	4311-4314	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-15	4314-4315	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-16	4315-4317	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
29-17	4317-4318	)	_	
29-18	4319-4327	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
29-19	4328-4336	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
29-20	4336-4337	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=The inclusion criteria for the MAP group were as follows: (a) they volunteered to detox from METH; (b) they met the criteria of substance-associated psychosis of ICD-10, but their course standard could be more than 1 month; (c) direct laboratory evidence (urine, blood, and hair) proved that they had a history of METH abuse; (d) they achieved the medium or serious level in ≥t items of delusion, hallucinatory behavior, grandiosity, suspiciousness/persecution, and unusual thought content.
30-1	4338-4341	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-2	4342-4351	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-3	4352-4360	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-4	4361-4364	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-5	4365-4368	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-6	4369-4372	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]	
30-7	4373-4378	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-8	4379-4383	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-9	4384-4386	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-10	4387-4394	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-11	4394-4395	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-12	4396-4397	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-13	4397-4398	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-14	4398-4399	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-15	4400-4404	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-16	4405-4416	volunteered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-17	4417-4419	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-18	4420-4425	detox	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-19	4426-4430	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-20	4431-4435	METH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-21	4435-4436	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-22	4437-4438	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-23	4438-4439	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-24	4439-4440	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-25	4441-4445	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-26	4446-4449	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-27	4450-4453	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-28	4454-4462	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-29	4463-4465	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
30-30	4466-4486	substance-associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-31	4487-4496	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-32	4497-4499	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-33	4500-4503	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#ImpulseControlDisorder[22]	
30-34	4503-4504	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#ImpulseControlDisorder[22]	
30-35	4504-4506	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#ImpulseControlDisorder[22]	
30-36	4506-4507	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-37	4508-4511	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-38	4512-4517	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-39	4518-4524	course	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-40	4525-4533	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-41	4534-4539	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-42	4540-4542	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-43	4543-4547	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-44	4548-4552	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-45	4553-4554	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-46	4555-4560	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-47	4560-4561	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-48	4562-4563	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-49	4563-4564	c	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-50	4564-4565	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-51	4566-4572	direct	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-52	4573-4583	laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-53	4584-4592	evidence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-54	4593-4594	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-55	4594-4599	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-56	4599-4600	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-57	4601-4606	blood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-58	4606-4607	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-59	4608-4611	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-60	4612-4616	hair	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-61	4616-4617	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-62	4618-4624	proved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-63	4625-4629	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-64	4630-4634	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-65	4635-4638	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-66	4639-4640	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-67	4641-4648	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-68	4649-4651	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-69	4652-4656	METH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-70	4657-4662	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-71	4662-4663	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-72	4664-4665	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-73	4665-4666	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-74	4666-4667	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-75	4668-4672	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-76	4673-4681	achieved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-77	4682-4685	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-78	4686-4692	medium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-79	4693-4695	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-80	4696-4703	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-81	4704-4709	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-82	4710-4712	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-83	4713-4714	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-84	4714-4715	t	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-85	4716-4721	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-86	4722-4724	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-87	4725-4733	delusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-88	4733-4734	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-89	4735-4748	hallucinatory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-90	4749-4757	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-91	4757-4758	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-92	4759-4770	grandiosity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-93	4770-4771	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-94	4772-4786	suspiciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-95	4786-4787	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-96	4787-4798	persecution	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-97	4798-4799	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-98	4800-4803	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-99	4804-4811	unusual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-100	4812-4819	thought	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-101	4820-4827	content	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
30-102	4827-4828	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=The exclusion criteria were as follow: (a) subjects had a history of SCZ, mood disorders, neurosis, or mental retardation; (b) they had a history of serious somatic diseases or organic brain diseases, such as stroke or brain injury; (c) they presented a seropositive test for HIV; (d) they were incompatible for MRI; (e) they abused harmful substances other than METH and nicotine; (f) they were delirious; (g) they had a history of epileptic seizure or had a family history of epilepsy; (h) they had used benzodiazepines 1 week prior to fMRI examination; (i) their head translation or rotation was more than 3 mm/3°.
31-1	4829-4832	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-2	4833-4842	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-3	4843-4851	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-4	4852-4856	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-5	4857-4859	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-6	4860-4866	follow	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-7	4866-4867	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-8	4868-4869	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-9	4869-4870	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-10	4870-4871	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-11	4872-4880	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-12	4881-4884	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-13	4885-4886	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-14	4887-4894	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-15	4895-4897	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-16	4898-4901	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-17	4901-4902	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-18	4903-4907	mood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-19	4908-4917	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-20	4917-4918	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-21	4919-4927	neurosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-22	4927-4928	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-23	4929-4931	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-24	4932-4938	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-25	4939-4950	retardation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-26	4950-4951	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-27	4952-4953	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-28	4953-4954	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-29	4954-4955	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-30	4956-4960	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-31	4961-4964	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-32	4965-4966	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-33	4967-4974	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-34	4975-4977	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-35	4978-4985	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-36	4986-4993	somatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-37	4994-5002	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-38	5003-5005	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-39	5006-5013	organic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-40	5014-5019	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-41	5020-5028	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-42	5028-5029	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-43	5030-5034	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-44	5035-5037	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-45	5038-5044	stroke	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-46	5045-5047	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-47	5048-5053	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-48	5054-5060	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-49	5060-5061	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-50	5062-5063	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-51	5063-5064	c	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-52	5064-5065	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-53	5066-5070	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-54	5071-5080	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-55	5081-5082	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-56	5083-5095	seropositive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-57	5096-5100	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-58	5101-5104	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-59	5105-5108	HIV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-60	5108-5109	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-61	5110-5111	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-62	5111-5112	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-63	5112-5113	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-64	5114-5118	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-65	5119-5123	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-66	5124-5136	incompatible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-67	5137-5140	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-68	5141-5144	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-69	5144-5145	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-70	5146-5147	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-71	5147-5148	e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-72	5148-5149	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-73	5150-5154	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-74	5155-5161	abused	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-75	5162-5169	harmful	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-76	5170-5180	substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-77	5181-5186	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-78	5187-5191	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-79	5192-5196	METH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-80	5197-5200	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-81	5201-5209	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-82	5209-5210	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-83	5211-5212	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-84	5212-5213	f	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-85	5213-5214	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-86	5215-5219	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-87	5220-5224	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-88	5225-5234	delirious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-89	5234-5235	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-90	5236-5237	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-91	5237-5238	g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-92	5238-5239	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-93	5240-5244	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-94	5245-5248	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-95	5249-5250	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-96	5251-5258	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-97	5259-5261	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-98	5262-5271	epileptic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-99	5272-5279	seizure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-100	5280-5282	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-101	5283-5286	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-102	5287-5288	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-103	5289-5295	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-104	5296-5303	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-105	5304-5306	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-106	5307-5315	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-107	5315-5316	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-108	5317-5318	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-109	5318-5319	h	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-110	5319-5320	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-111	5321-5325	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-112	5326-5329	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-113	5330-5334	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-114	5335-5350	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-115	5351-5352	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-116	5353-5357	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-117	5358-5363	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-118	5364-5366	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-119	5367-5371	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-120	5372-5383	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-121	5383-5384	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-122	5385-5386	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-123	5386-5387	i	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-124	5387-5388	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-125	5389-5394	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-126	5395-5399	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-127	5400-5411	translation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-128	5412-5414	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-129	5415-5423	rotation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-130	5424-5427	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-131	5428-5432	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-132	5433-5437	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-133	5438-5439	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-134	5440-5442	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-135	5442-5443	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-136	5443-5444	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-137	5444-5445	°	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
31-138	5445-5446	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=The inclusion and exclusion criteria of SCZ patients were similar to the MAP group, except that they met the criteria for SCZ according to ICD-10.
32-1	5447-5450	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-2	5451-5460	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-3	5461-5464	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-4	5465-5474	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-5	5475-5483	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-6	5484-5486	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-7	5487-5490	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
32-8	5491-5499	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-9	5500-5504	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-10	5505-5512	similar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-11	5513-5515	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-12	5516-5519	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-13	5520-5523	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-14	5524-5529	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-15	5529-5530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-16	5531-5537	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-17	5538-5542	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-18	5543-5547	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-19	5548-5551	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-20	5552-5555	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-21	5556-5564	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-22	5565-5568	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-23	5569-5572	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[24]	
32-24	5573-5582	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-25	5583-5585	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-26	5586-5589	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-27	5589-5590	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-28	5590-5592	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
32-29	5592-5593	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=Informed consent from all participants was obtained before the neuroimaging and other clinical assessments.
33-1	5594-5602	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-2	5603-5610	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-3	5611-5615	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-4	5616-5619	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-5	5620-5632	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-6	5633-5636	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-7	5637-5645	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-8	5646-5652	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-9	5653-5656	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-10	5657-5669	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-11	5670-5673	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-12	5674-5679	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-13	5680-5688	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-14	5689-5700	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
33-15	5700-5701	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=This retrospective study was approved by the local Ethics Committee and the Institutional Review Board, and all participants signed the informed consent before participating in this study.
34-1	5702-5706	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-2	5707-5720	retrospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-3	5721-5726	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-4	5727-5730	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-5	5731-5739	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-6	5740-5742	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-7	5743-5746	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-8	5747-5752	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-9	5753-5759	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-10	5760-5769	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-11	5770-5773	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-12	5774-5777	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-13	5778-5791	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-14	5792-5798	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-15	5799-5804	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-16	5804-5805	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-17	5806-5809	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-18	5810-5813	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-19	5814-5826	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-20	5827-5833	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-21	5834-5837	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-22	5838-5846	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-23	5847-5854	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-24	5855-5861	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-25	5862-5875	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-26	5876-5878	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-27	5879-5883	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-28	5884-5889	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
34-29	5889-5890	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Data collection and follow-up
#Text=Personal information on demographics, history of psychoactive drug use, and history of body/mental disease were collected.
35-1	5891-5895	Data	_	
35-2	5896-5906	collection	_	
35-3	5907-5910	and	_	
35-4	5911-5920	follow-up	_	
35-5	5921-5929	Personal	_	
35-6	5930-5941	information	_	
35-7	5942-5944	on	_	
35-8	5945-5957	demographics	_	
35-9	5957-5958	,	_	
35-10	5959-5966	history	_	
35-11	5967-5969	of	_	
35-12	5970-5982	psychoactive	_	
35-13	5983-5987	drug	_	
35-14	5988-5991	use	_	
35-15	5991-5992	,	_	
35-16	5993-5996	and	_	
35-17	5997-6004	history	_	
35-18	6005-6007	of	_	
35-19	6008-6012	body	_	
35-20	6012-6013	/	_	
35-21	6013-6019	mental	_	
35-22	6020-6027	disease	_	
35-23	6028-6032	were	_	
35-24	6033-6042	collected	_	
35-25	6042-6043	.	_	

#Text=In addition, detailed information on METH use and its relationship with onset and disappearance of psychotic symptoms was obtained after interviewing the patients.
36-1	6044-6046	In	_	
36-2	6047-6055	addition	_	
36-3	6055-6056	,	_	
36-4	6057-6065	detailed	_	
36-5	6066-6077	information	_	
36-6	6078-6080	on	_	
36-7	6081-6085	METH	_	
36-8	6086-6089	use	_	
36-9	6090-6093	and	_	
36-10	6094-6097	its	_	
36-11	6098-6110	relationship	_	
36-12	6111-6115	with	_	
36-13	6116-6121	onset	_	
36-14	6122-6125	and	_	
36-15	6126-6139	disappearance	_	
36-16	6140-6142	of	_	
36-17	6143-6152	psychotic	_	
36-18	6153-6161	symptoms	_	
36-19	6162-6165	was	_	
36-20	6166-6174	obtained	_	
36-21	6175-6180	after	_	
36-22	6181-6193	interviewing	_	
36-23	6194-6197	the	_	
36-24	6198-6206	patients	_	
36-25	6206-6207	.	_	

#Text=Moreover, the history of psychiatric disorders and serious somatic diseases were recorded.
37-1	6208-6216	Moreover	_	
37-2	6216-6217	,	_	
37-3	6218-6221	the	_	
37-4	6222-6229	history	_	
37-5	6230-6232	of	_	
37-6	6233-6244	psychiatric	_	
37-7	6245-6254	disorders	_	
37-8	6255-6258	and	_	
37-9	6259-6266	serious	_	
37-10	6267-6274	somatic	_	
37-11	6275-6283	diseases	_	
37-12	6284-6288	were	_	
37-13	6289-6297	recorded	_	
37-14	6297-6298	.	_	

#Text=Participants were followed up for 6 months after their first interview.
38-1	6299-6311	Participants	_	
38-2	6312-6316	were	_	
38-3	6317-6325	followed	_	
38-4	6326-6328	up	_	
38-5	6329-6332	for	_	
38-6	6333-6334	6	_	
38-7	6335-6341	months	_	
38-8	6342-6347	after	_	
38-9	6348-6353	their	_	
38-10	6354-6359	first	_	
38-11	6360-6369	interview	_	
38-12	6369-6370	.	_	

#Text=Clinical evaluation
#Text=The diagnoses of MAP and SCZ were confirmed by 2 senior attending psychiatrists, and the severity of the clinical symptoms was assessed prior to the fMRI scan using the Positive and Negative Syndrome Scale (PANSS) and the Mini International Neuropsychiatric Interview (MINI).
39-1	6371-6379	Clinical	_	
39-2	6380-6390	evaluation	_	
39-3	6391-6394	The	_	
39-4	6395-6404	diagnoses	_	
39-5	6405-6407	of	_	
39-6	6408-6411	MAP	_	
39-7	6412-6415	and	_	
39-8	6416-6419	SCZ	_	
39-9	6420-6424	were	_	
39-10	6425-6434	confirmed	_	
39-11	6435-6437	by	_	
39-12	6438-6439	2	_	
39-13	6440-6446	senior	_	
39-14	6447-6456	attending	_	
39-15	6457-6470	psychiatrists	_	
39-16	6470-6471	,	_	
39-17	6472-6475	and	_	
39-18	6476-6479	the	_	
39-19	6480-6488	severity	_	
39-20	6489-6491	of	_	
39-21	6492-6495	the	_	
39-22	6496-6504	clinical	_	
39-23	6505-6513	symptoms	_	
39-24	6514-6517	was	_	
39-25	6518-6526	assessed	_	
39-26	6527-6532	prior	_	
39-27	6533-6535	to	_	
39-28	6536-6539	the	_	
39-29	6540-6544	fMRI	_	
39-30	6545-6549	scan	_	
39-31	6550-6555	using	_	
39-32	6556-6559	the	_	
39-33	6560-6568	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-34	6569-6572	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-35	6573-6581	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-36	6582-6590	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-37	6591-6596	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-38	6597-6598	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-39	6598-6603	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-40	6603-6604	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[26]	
39-41	6605-6608	and	_	
39-42	6609-6612	the	_	
39-43	6613-6617	Mini	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-44	6618-6631	International	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-45	6632-6648	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-46	6649-6658	Interview	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-47	6659-6660	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-48	6660-6664	MINI	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-49	6664-6665	)	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
39-50	6665-6666	.	_	

#Text=MRI acquisition
#Text=The MRI scans were performed on a 3.0T Signa HDxt scanner (GE Healthcare, America) with an 8-channel head coil MRI scanner at the Department of Psychology, Qiqihar Mental Health Center.
40-1	6667-6670	MRI	_	
40-2	6671-6682	acquisition	_	
40-3	6683-6686	The	_	
40-4	6687-6690	MRI	_	
40-5	6691-6696	scans	_	
40-6	6697-6701	were	_	
40-7	6702-6711	performed	_	
40-8	6712-6714	on	_	
40-9	6715-6716	a	_	
40-10	6717-6721	3.0T	_	
40-11	6722-6727	Signa	_	
40-12	6728-6732	HDxt	_	
40-13	6733-6740	scanner	_	
40-14	6741-6742	(	_	
40-15	6742-6744	GE	_	
40-16	6745-6755	Healthcare	_	
40-17	6755-6756	,	_	
40-18	6757-6764	America	_	
40-19	6764-6765	)	_	
40-20	6766-6770	with	_	
40-21	6771-6773	an	_	
40-22	6774-6775	8	_	
40-23	6775-6776	-	_	
40-24	6776-6783	channel	_	
40-25	6784-6788	head	_	
40-26	6789-6793	coil	_	
40-27	6794-6797	MRI	_	
40-28	6798-6805	scanner	_	
40-29	6806-6808	at	_	
40-30	6809-6812	the	_	
40-31	6813-6823	Department	_	
40-32	6824-6826	of	_	
40-33	6827-6837	Psychology	_	
40-34	6837-6838	,	_	
40-35	6839-6846	Qiqihar	_	
40-36	6847-6853	Mental	_	
40-37	6854-6860	Health	_	
40-38	6861-6867	Center	_	
40-39	6867-6868	.	_	

#Text=The anatomical MRIs were administered with T1-weighted sequence for 300 s using the fast spin echo sequence.
41-1	6869-6872	The	_	
41-2	6873-6883	anatomical	_	
41-3	6884-6888	MRIs	_	
41-4	6889-6893	were	_	
41-5	6894-6906	administered	_	
41-6	6907-6911	with	_	
41-7	6912-6914	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
41-8	6914-6915	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
41-9	6915-6923	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
41-10	6924-6932	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[28]	
41-11	6933-6936	for	_	
41-12	6937-6940	300	_	
41-13	6941-6942	s	_	
41-14	6943-6948	using	_	
41-15	6949-6952	the	_	
41-16	6953-6957	fast	_	
41-17	6958-6962	spin	_	
41-18	6963-6967	echo	_	
41-19	6968-6976	sequence	_	
41-20	6976-6977	.	_	

#Text=Parameters for the OAx T1 FLAIR were shown as: repetition time (TR)=2300 ms, echo time (TE)=2.96 ms, field of vision (FOV)=256×256 cm, image matrix=256×256, voxel dimensions=1.0×1.0×1.0 cm, layer thickness=1.0 mm, layer gap=0.0 mm, and 192 layers in total.
42-1	6978-6988	Parameters	_	
42-2	6989-6992	for	_	
42-3	6993-6996	the	_	
42-4	6997-7000	OAx	_	
42-5	7001-7003	T1	_	
42-6	7004-7009	FLAIR	_	
42-7	7010-7014	were	_	
42-8	7015-7020	shown	_	
42-9	7021-7023	as	_	
42-10	7023-7024	:	_	
42-11	7025-7035	repetition	_	
42-12	7036-7040	time	_	
42-13	7041-7042	(	_	
42-14	7042-7044	TR	_	
42-15	7044-7045	)	_	
42-16	7045-7046	=	_	
42-17	7046-7050	2300	_	
42-18	7051-7053	ms	_	
42-19	7053-7054	,	_	
42-20	7055-7059	echo	_	
42-21	7060-7064	time	_	
42-22	7065-7066	(	_	
42-23	7066-7068	TE	_	
42-24	7068-7069	)	_	
42-25	7069-7070	=	_	
42-26	7070-7074	2.96	_	
42-27	7075-7077	ms	_	
42-28	7077-7078	,	_	
42-29	7079-7084	field	_	
42-30	7085-7087	of	_	
42-31	7088-7094	vision	_	
42-32	7095-7096	(	_	
42-33	7096-7099	FOV	_	
42-34	7099-7100	)	_	
42-35	7100-7101	=	_	
42-36	7101-7104	256	_	
42-37	7104-7105	×	_	
42-38	7105-7108	256	_	
42-39	7109-7111	cm	_	
42-40	7111-7112	,	_	
42-41	7113-7118	image	_	
42-42	7119-7125	matrix	_	
42-43	7125-7126	=	_	
42-44	7126-7129	256	_	
42-45	7129-7130	×	_	
42-46	7130-7133	256	_	
42-47	7133-7134	,	_	
42-48	7135-7140	voxel	_	
42-49	7141-7151	dimensions	_	
42-50	7151-7152	=	_	
42-51	7152-7155	1.0	_	
42-52	7155-7156	×	_	
42-53	7156-7159	1.0	_	
42-54	7159-7160	×	_	
42-55	7160-7163	1.0	_	
42-56	7164-7166	cm	_	
42-57	7166-7167	,	_	
42-58	7168-7173	layer	_	
42-59	7174-7183	thickness	_	
42-60	7183-7184	=	_	
42-61	7184-7187	1.0	_	
42-62	7188-7190	mm	_	
42-63	7190-7191	,	_	
42-64	7192-7197	layer	_	
42-65	7198-7201	gap	_	
42-66	7201-7202	=	_	
42-67	7202-7205	0.0	_	
42-68	7206-7208	mm	_	
42-69	7208-7209	,	_	
42-70	7210-7213	and	_	
42-71	7214-7217	192	_	
42-72	7218-7224	layers	_	
42-73	7225-7227	in	_	
42-74	7228-7233	total	_	
42-75	7233-7234	.	_	

#Text=Then, rs-fMRIs were obtained by 400-second-BOLD-fMRI scanning with echo planar imaging (EPI) sequence, and the scanning orientation was parallel to the anatomical MRI.
43-1	7235-7239	Then	_	
43-2	7239-7240	,	_	
43-3	7241-7249	rs-fMRIs	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
43-4	7250-7254	were	_	
43-5	7255-7263	obtained	_	
43-6	7264-7266	by	_	
43-7	7267-7270	400	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-8	7270-7271	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-9	7271-7287	second-BOLD-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-10	7288-7296	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-11	7297-7301	with	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-12	7302-7306	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-13	7307-7313	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-14	7314-7321	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-15	7322-7323	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-16	7323-7326	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-17	7326-7327	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-18	7328-7336	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-19	7336-7337	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[29]	
43-20	7338-7341	and	_	
43-21	7342-7345	the	_	
43-22	7346-7354	scanning	_	
43-23	7355-7366	orientation	_	
43-24	7367-7370	was	_	
43-25	7371-7379	parallel	_	
43-26	7380-7382	to	_	
43-27	7383-7386	the	_	
43-28	7387-7397	anatomical	_	
43-29	7398-7401	MRI	_	
43-30	7401-7402	.	_	

#Text=All participants were required to close their eyes, lie down, rest without thinking, and keep their head still.
44-1	7403-7406	All	_	
44-2	7407-7419	participants	_	
44-3	7420-7424	were	_	
44-4	7425-7433	required	_	
44-5	7434-7436	to	_	
44-6	7437-7442	close	_	
44-7	7443-7448	their	_	
44-8	7449-7453	eyes	_	
44-9	7453-7454	,	_	
44-10	7455-7458	lie	_	
44-11	7459-7463	down	_	
44-12	7463-7464	,	_	
44-13	7465-7469	rest	_	
44-14	7470-7477	without	_	
44-15	7478-7486	thinking	_	
44-16	7486-7487	,	_	
44-17	7488-7491	and	_	
44-18	7492-7496	keep	_	
44-19	7497-7502	their	_	
44-20	7503-7507	head	_	
44-21	7508-7513	still	_	
44-22	7513-7514	.	_	

#Text=The parameters were set as follow: TR=2000 ms, TE=30 ms, flip angle (FA)=90°, FOV=220×220 mm, image matrix=64×64, layer thickness=4.0 mm, and 33 layers in total.
45-1	7515-7518	The	_	
45-2	7519-7529	parameters	_	
45-3	7530-7534	were	_	
45-4	7535-7538	set	_	
45-5	7539-7541	as	_	
45-6	7542-7548	follow	_	
45-7	7548-7549	:	_	
45-8	7550-7552	TR	_	
45-9	7552-7553	=	_	
45-10	7553-7557	2000	_	
45-11	7558-7560	ms	_	
45-12	7560-7561	,	_	
45-13	7562-7564	TE	_	
45-14	7564-7565	=	_	
45-15	7565-7567	30	_	
45-16	7568-7570	ms	_	
45-17	7570-7571	,	_	
45-18	7572-7576	flip	_	
45-19	7577-7582	angle	_	
45-20	7583-7584	(	_	
45-21	7584-7586	FA	_	
45-22	7586-7587	)	_	
45-23	7587-7588	=	_	
45-24	7588-7590	90	_	
45-25	7590-7591	°	_	
45-26	7591-7592	,	_	
45-27	7593-7596	FOV	_	
45-28	7596-7597	=	_	
45-29	7597-7600	220	_	
45-30	7600-7601	×	_	
45-31	7601-7604	220	_	
45-32	7605-7607	mm	_	
45-33	7607-7608	,	_	
45-34	7609-7614	image	_	
45-35	7615-7621	matrix	_	
45-36	7621-7622	=	_	
45-37	7622-7624	64	_	
45-38	7624-7625	×	_	
45-39	7625-7627	64	_	
45-40	7627-7628	,	_	
45-41	7629-7634	layer	_	
45-42	7635-7644	thickness	_	
45-43	7644-7645	=	_	
45-44	7645-7648	4.0	_	
45-45	7649-7651	mm	_	
45-46	7651-7652	,	_	
45-47	7653-7656	and	_	
45-48	7657-7659	33	_	
45-49	7660-7666	layers	_	
45-50	7667-7669	in	_	
45-51	7670-7675	total	_	
45-52	7675-7676	.	_	

#Text=For each participant, the fMRI scanning lasted for approximately 6 min.
46-1	7677-7680	For	_	
46-2	7681-7685	each	_	
46-3	7686-7697	participant	_	
46-4	7697-7698	,	_	
46-5	7699-7702	the	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
46-6	7703-7707	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
46-7	7708-7716	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
46-8	7717-7723	lasted	_	
46-9	7724-7727	for	_	
46-10	7728-7741	approximately	_	
46-11	7742-7743	6	_	
46-12	7744-7747	min	_	
46-13	7747-7748	.	_	

#Text=Image preprocessing
#Text=All the images were reconstructed and transformed to NIFTI by using the software SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) running on the MATLAB 2011b.
47-1	7749-7754	Image	_	
47-2	7755-7768	preprocessing	_	
47-3	7769-7772	All	_	
47-4	7773-7776	the	_	
47-5	7777-7783	images	_	
47-6	7784-7788	were	_	
47-7	7789-7802	reconstructed	_	
47-8	7803-7806	and	_	
47-9	7807-7818	transformed	_	
47-10	7819-7821	to	_	
47-11	7822-7827	NIFTI	_	
47-12	7828-7830	by	_	
47-13	7831-7836	using	_	
47-14	7837-7840	the	_	
47-15	7841-7849	software	_	
47-16	7850-7854	SPM8	_	
47-17	7855-7856	(	_	
47-18	7856-7860	http	_	
47-19	7860-7861	:	_	
47-20	7861-7862	/	_	
47-21	7862-7863	/	_	
47-22	7863-7884	www.fil.ion.ucl.ac.uk	_	
47-23	7884-7885	/	_	
47-24	7885-7888	spm	_	
47-25	7888-7889	/	_	
47-26	7889-7897	software	_	
47-27	7897-7898	/	_	
47-28	7898-7902	spm8	_	
47-29	7902-7903	/	_	
47-30	7903-7904	)	_	
47-31	7905-7912	running	_	
47-32	7913-7915	on	_	
47-33	7916-7919	the	_	
47-34	7920-7926	MATLAB	_	
47-35	7927-7932	2011b	_	
47-36	7932-7933	.	_	

#Text=Structural image preprocessing and the gray matter density (GMD) were performed using the same software, while the functional image preprocessing, individual ReHo calculation and whole-brain functional connectivity (FC) were analyzed using DPARSF 2.0 software (http://www.nitrc.org/projects/dparsf).
48-1	7934-7944	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[31]	
48-2	7945-7950	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[31]	
48-3	7951-7964	preprocessing	_	
48-4	7965-7968	and	_	
48-5	7969-7972	the	_	
48-6	7973-7977	gray	_	
48-7	7978-7984	matter	_	
48-8	7985-7992	density	_	
48-9	7993-7994	(	_	
48-10	7994-7997	GMD	_	
48-11	7997-7998	)	_	
48-12	7999-8003	were	_	
48-13	8004-8013	performed	_	
48-14	8014-8019	using	_	
48-15	8020-8023	the	_	
48-16	8024-8028	same	_	
48-17	8029-8037	software	_	
48-18	8037-8038	,	_	
48-19	8039-8044	while	_	
48-20	8045-8048	the	_	
48-21	8049-8059	functional	_	
48-22	8060-8065	image	_	
48-23	8066-8079	preprocessing	_	
48-24	8079-8080	,	_	
48-25	8081-8091	individual	_	
48-26	8092-8096	ReHo	_	
48-27	8097-8108	calculation	_	
48-28	8109-8112	and	_	
48-29	8113-8124	whole-brain	_	
48-30	8125-8135	functional	_	
48-31	8136-8148	connectivity	_	
48-32	8149-8150	(	_	
48-33	8150-8152	FC	_	
48-34	8152-8153	)	_	
48-35	8154-8158	were	_	
48-36	8159-8167	analyzed	_	
48-37	8168-8173	using	_	
48-38	8174-8180	DPARSF	_	
48-39	8181-8184	2.0	_	
48-40	8185-8193	software	_	
48-41	8194-8195	(	_	
48-42	8195-8199	http	_	
48-43	8199-8200	:	_	
48-44	8200-8201	/	_	
48-45	8201-8202	/	_	
48-46	8202-8215	www.nitrc.org	_	
48-47	8215-8216	/	_	
48-48	8216-8224	projects	_	
48-49	8224-8225	/	_	
48-50	8225-8231	dparsf	_	
48-51	8231-8232	)	_	
48-52	8232-8233	.	_	

#Text=GMD
#Text=The structural images were divided into cerebrospinal fluid, gray matter (GM), and white matter using the unified segment.
49-1	8234-8237	GMD	_	
49-2	8238-8241	The	_	
49-3	8242-8252	structural	_	
49-4	8253-8259	images	_	
49-5	8260-8264	were	_	
49-6	8265-8272	divided	_	
49-7	8273-8277	into	_	
49-8	8278-8291	cerebrospinal	_	
49-9	8292-8297	fluid	_	
49-10	8297-8298	,	_	
49-11	8299-8303	gray	_	
49-12	8304-8310	matter	_	
49-13	8311-8312	(	_	
49-14	8312-8314	GM	_	
49-15	8314-8315	)	_	
49-16	8315-8316	,	_	
49-17	8317-8320	and	_	
49-18	8321-8326	white	_	
49-19	8327-8333	matter	_	
49-20	8334-8339	using	_	
49-21	8340-8343	the	_	
49-22	8344-8351	unified	_	
49-23	8352-8359	segment	_	
49-24	8359-8360	.	_	

#Text=According to non-linear methods, the segmented subareas were spatially normalized to standard brain space, and were smoothed by a 6×6×6 FWHM Gaussian kernel to obtain a GM concentration map.
50-1	8361-8370	According	_	
50-2	8371-8373	to	_	
50-3	8374-8384	non-linear	_	
50-4	8385-8392	methods	_	
50-5	8392-8393	,	_	
50-6	8394-8397	the	_	
50-7	8398-8407	segmented	_	
50-8	8408-8416	subareas	_	
50-9	8417-8421	were	_	
50-10	8422-8431	spatially	_	
50-11	8432-8442	normalized	_	
50-12	8443-8445	to	_	
50-13	8446-8454	standard	_	
50-14	8455-8460	brain	_	
50-15	8461-8466	space	_	
50-16	8466-8467	,	_	
50-17	8468-8471	and	_	
50-18	8472-8476	were	_	
50-19	8477-8485	smoothed	_	
50-20	8486-8488	by	_	
50-21	8489-8490	a	_	
50-22	8491-8492	6	_	
50-23	8492-8493	×	_	
50-24	8493-8494	6	_	
50-25	8494-8495	×	_	
50-26	8495-8496	6	_	
50-27	8497-8501	FWHM	_	
50-28	8502-8510	Gaussian	_	
50-29	8511-8517	kernel	_	
50-30	8518-8520	to	_	
50-31	8521-8527	obtain	_	
50-32	8528-8529	a	_	
50-33	8530-8532	GM	_	
50-34	8533-8546	concentration	_	
50-35	8547-8550	map	_	
50-36	8550-8551	.	_	

#Text=The GMD density was analyzed using Marsbar software.
51-1	8552-8555	The	_	
51-2	8556-8559	GMD	_	
51-3	8560-8567	density	_	
51-4	8568-8571	was	_	
51-5	8572-8580	analyzed	_	
51-6	8581-8586	using	_	
51-7	8587-8594	Marsbar	_	
51-8	8595-8603	software	_	
51-9	8603-8604	.	_	

#Text=Individual ReHo
#Text=For functional image preprocessing, the first 10 volumes of the EPI sequence were discarded to avoid signal instability.
52-1	8605-8615	Individual	_	
52-2	8616-8620	ReHo	_	
52-3	8621-8624	For	_	
52-4	8625-8635	functional	_	
52-5	8636-8641	image	_	
52-6	8642-8655	preprocessing	_	
52-7	8655-8656	,	_	
52-8	8657-8660	the	_	
52-9	8661-8666	first	_	
52-10	8667-8669	10	_	
52-11	8670-8677	volumes	_	
52-12	8678-8680	of	_	
52-13	8681-8684	the	_	
52-14	8685-8688	EPI	_	
52-15	8689-8697	sequence	_	
52-16	8698-8702	were	_	
52-17	8703-8712	discarded	_	
52-18	8713-8715	to	_	
52-19	8716-8721	avoid	_	
52-20	8722-8728	signal	_	
52-21	8729-8740	instability	_	
52-22	8740-8741	.	_	

#Text=Slice timing was conducted to correct the remaining volumes, and head realign was used to reject abnormal participants who had more than 3 mm of motion or 3.0° of rotation.
53-1	8742-8747	Slice	_	
53-2	8748-8754	timing	_	
53-3	8755-8758	was	_	
53-4	8759-8768	conducted	_	
53-5	8769-8771	to	_	
53-6	8772-8779	correct	_	
53-7	8780-8783	the	_	
53-8	8784-8793	remaining	_	
53-9	8794-8801	volumes	_	
53-10	8801-8802	,	_	
53-11	8803-8806	and	_	
53-12	8807-8811	head	_	
53-13	8812-8819	realign	_	
53-14	8820-8823	was	_	
53-15	8824-8828	used	_	
53-16	8829-8831	to	_	
53-17	8832-8838	reject	_	
53-18	8839-8847	abnormal	_	
53-19	8848-8860	participants	_	
53-20	8861-8864	who	_	
53-21	8865-8868	had	_	
53-22	8869-8873	more	_	
53-23	8874-8878	than	_	
53-24	8879-8880	3	_	
53-25	8881-8883	mm	_	
53-26	8884-8886	of	_	
53-27	8887-8893	motion	_	
53-28	8894-8896	or	_	
53-29	8897-8900	3.0	_	
53-30	8900-8901	°	_	
53-31	8902-8904	of	_	
53-32	8905-8913	rotation	_	
53-33	8913-8914	.	_	

#Text=The realigned sequences were spatially normalized to the MNI (Montreal Neurological Institute) coordinate and voxels were resampled to 3×3×3 mm3.
54-1	8915-8918	The	_	
54-2	8919-8928	realigned	_	
54-3	8929-8938	sequences	_	
54-4	8939-8943	were	_	
54-5	8944-8953	spatially	_	
54-6	8954-8964	normalized	_	
54-7	8965-8967	to	_	
54-8	8968-8971	the	_	
54-9	8972-8975	MNI	_	
54-10	8976-8977	(	_	
54-11	8977-8985	Montreal	_	
54-12	8986-8998	Neurological	_	
54-13	8999-9008	Institute	_	
54-14	9008-9009	)	_	
54-15	9010-9020	coordinate	_	
54-16	9021-9024	and	_	
54-17	9025-9031	voxels	_	
54-18	9032-9036	were	_	
54-19	9037-9046	resampled	_	
54-20	9047-9049	to	_	
54-21	9050-9051	3	_	
54-22	9051-9052	×	_	
54-23	9052-9053	3	_	
54-24	9053-9054	×	_	
54-25	9054-9055	3	_	
54-26	9056-9059	mm3	_	
54-27	9059-9060	.	_	

#Text=Then, images were band-pass filtered (0.01–0.08 Hz) to reduce low-frequency drift and physiological high-frequency noise, including breath and heart beats.
55-1	9061-9065	Then	_	
55-2	9065-9066	,	_	
55-3	9067-9073	images	_	
55-4	9074-9078	were	_	
55-5	9079-9088	band-pass	_	
55-6	9089-9097	filtered	_	
55-7	9098-9099	(	_	
55-8	9099-9103	0.01	_	
55-9	9103-9104	–	_	
55-10	9104-9108	0.08	_	
55-11	9109-9111	Hz	_	
55-12	9111-9112	)	_	
55-13	9113-9115	to	_	
55-14	9116-9122	reduce	_	
55-15	9123-9136	low-frequency	_	
55-16	9137-9142	drift	_	
55-17	9143-9146	and	_	
55-18	9147-9160	physiological	_	
55-19	9161-9175	high-frequency	_	
55-20	9176-9181	noise	_	
55-21	9181-9182	,	_	
55-22	9183-9192	including	_	
55-23	9193-9199	breath	_	
55-24	9200-9203	and	_	
55-25	9204-9209	heart	_	
55-26	9210-9215	beats	_	
55-27	9215-9216	.	_	

#Text=Then, signals were regressed out before ReHo computation, including head parameter in 6 dimensions, white matter, cerebrospinal fluid (CSF), and global brain.
56-1	9217-9221	Then	_	
56-2	9221-9222	,	_	
56-3	9223-9230	signals	_	
56-4	9231-9235	were	_	
56-5	9236-9245	regressed	_	
56-6	9246-9249	out	_	
56-7	9250-9256	before	_	
56-8	9257-9261	ReHo	_	
56-9	9262-9273	computation	_	
56-10	9273-9274	,	_	
56-11	9275-9284	including	_	
56-12	9285-9289	head	_	
56-13	9290-9299	parameter	_	
56-14	9300-9302	in	_	
56-15	9303-9304	6	_	
56-16	9305-9315	dimensions	_	
56-17	9315-9316	,	_	
56-18	9317-9322	white	_	
56-19	9323-9329	matter	_	
56-20	9329-9330	,	_	
56-21	9331-9344	cerebrospinal	_	
56-22	9345-9350	fluid	_	
56-23	9351-9352	(	_	
56-24	9352-9355	CSF	_	
56-25	9355-9356	)	_	
56-26	9356-9357	,	_	
56-27	9358-9361	and	_	
56-28	9362-9368	global	_	
56-29	9369-9374	brain	_	
56-30	9374-9375	.	_	

#Text=Individual ReHo was calculated with the Kendall’s coefficient concordance (KCC) method.
57-1	9376-9386	Individual	_	
57-2	9387-9391	ReHo	_	
57-3	9392-9395	was	_	
57-4	9396-9406	calculated	_	
57-5	9407-9411	with	_	
57-6	9412-9415	the	_	
57-7	9416-9423	Kendall	_	
57-8	9423-9424	’	_	
57-9	9424-9425	s	_	
57-10	9426-9437	coefficient	_	
57-11	9438-9449	concordance	_	
57-12	9450-9451	(	_	
57-13	9451-9454	KCC	_	
57-14	9454-9455	)	_	
57-15	9456-9462	method	_	
57-16	9462-9463	.	_	

#Text=ReHo maps were normalized by dividing KCC among each voxel by the averaged ReHo of the entire brain and were smoothed by a 4×4×4 FWHM Gaussian kernel to avoid the spatial noise and the false data caused by spatial normalization.
58-1	9464-9468	ReHo	_	
58-2	9469-9473	maps	_	
58-3	9474-9478	were	_	
58-4	9479-9489	normalized	_	
58-5	9490-9492	by	_	
58-6	9493-9501	dividing	_	
58-7	9502-9505	KCC	_	
58-8	9506-9511	among	_	
58-9	9512-9516	each	_	
58-10	9517-9522	voxel	_	
58-11	9523-9525	by	_	
58-12	9526-9529	the	_	
58-13	9530-9538	averaged	_	
58-14	9539-9543	ReHo	_	
58-15	9544-9546	of	_	
58-16	9547-9550	the	_	
58-17	9551-9557	entire	_	
58-18	9558-9563	brain	_	
58-19	9564-9567	and	_	
58-20	9568-9572	were	_	
58-21	9573-9581	smoothed	_	
58-22	9582-9584	by	_	
58-23	9585-9586	a	_	
58-24	9587-9588	4	_	
58-25	9588-9589	×	_	
58-26	9589-9590	4	_	
58-27	9590-9591	×	_	
58-28	9591-9592	4	_	
58-29	9593-9597	FWHM	_	
58-30	9598-9606	Gaussian	_	
58-31	9607-9613	kernel	_	
58-32	9614-9616	to	_	
58-33	9617-9622	avoid	_	
58-34	9623-9626	the	_	
58-35	9627-9634	spatial	_	
58-36	9635-9640	noise	_	
58-37	9641-9644	and	_	
58-38	9645-9648	the	_	
58-39	9649-9654	false	_	
58-40	9655-9659	data	_	
58-41	9660-9666	caused	_	
58-42	9667-9669	by	_	
58-43	9670-9677	spatial	_	
58-44	9678-9691	normalization	_	
58-45	9691-9692	.	_	

#Text=Seed ROI FCM
#Text=According to the analysis of ReHo, group differences in ReHo were found, and points with peak values in sub-regions were defined as seeds.
59-1	9693-9697	Seed	_	
59-2	9698-9701	ROI	_	
59-3	9702-9705	FCM	_	
59-4	9706-9715	According	_	
59-5	9716-9718	to	_	
59-6	9719-9722	the	_	
59-7	9723-9731	analysis	_	
59-8	9732-9734	of	_	
59-9	9735-9739	ReHo	_	
59-10	9739-9740	,	_	
59-11	9741-9746	group	_	
59-12	9747-9758	differences	_	
59-13	9759-9761	in	_	
59-14	9762-9766	ReHo	_	
59-15	9767-9771	were	_	
59-16	9772-9777	found	_	
59-17	9777-9778	,	_	
59-18	9779-9782	and	_	
59-19	9783-9789	points	_	
59-20	9790-9794	with	_	
59-21	9795-9799	peak	_	
59-22	9800-9806	values	_	
59-23	9807-9809	in	_	
59-24	9810-9821	sub-regions	_	
59-25	9822-9826	were	_	
59-26	9827-9834	defined	_	
59-27	9835-9837	as	_	
59-28	9838-9843	seeds	_	
59-29	9843-9844	.	_	

#Text=Spheres with a 6-mm radius and with the seeds as the center were designated as the regions of interest (ROIs).
60-1	9845-9852	Spheres	_	
60-2	9853-9857	with	_	
60-3	9858-9859	a	_	
60-4	9860-9861	6	_	
60-5	9861-9862	-	_	
60-6	9862-9864	mm	_	
60-7	9865-9871	radius	_	
60-8	9872-9875	and	_	
60-9	9876-9880	with	_	
60-10	9881-9884	the	_	
60-11	9885-9890	seeds	_	
60-12	9891-9893	as	_	
60-13	9894-9897	the	_	
60-14	9898-9904	center	_	
60-15	9905-9909	were	_	
60-16	9910-9920	designated	_	
60-17	9921-9923	as	_	
60-18	9924-9927	the	_	
60-19	9928-9935	regions	_	
60-20	9936-9938	of	_	
60-21	9939-9947	interest	_	
60-22	9948-9949	(	_	
60-23	9949-9953	ROIs	_	
60-24	9953-9954	)	_	
60-25	9954-9955	.	_	

#Text=Each voxel in an ROI was calculated as the mean value according to the time sequence.
61-1	9956-9960	Each	_	
61-2	9961-9966	voxel	_	
61-3	9967-9969	in	_	
61-4	9970-9972	an	_	
61-5	9973-9976	ROI	_	
61-6	9977-9980	was	_	
61-7	9981-9991	calculated	_	
61-8	9992-9994	as	_	
61-9	9995-9998	the	_	
61-10	9999-10003	mean	_	
61-11	10004-10009	value	_	
61-12	10010-10019	according	_	
61-13	10020-10022	to	_	
61-14	10023-10026	the	_	
61-15	10027-10031	time	_	
61-16	10032-10040	sequence	_	
61-17	10040-10041	.	_	

#Text=Pearson’s correlation analysis was performed to obtain the whole-brain correlation maps, and Fisher Z translation was calculated to receive whole-brain functional connectivity maps (FCM).
62-1	10042-10049	Pearson	_	
62-2	10049-10050	’	_	
62-3	10050-10051	s	_	
62-4	10052-10063	correlation	_	
62-5	10064-10072	analysis	_	
62-6	10073-10076	was	_	
62-7	10077-10086	performed	_	
62-8	10087-10089	to	_	
62-9	10090-10096	obtain	_	
62-10	10097-10100	the	_	
62-11	10101-10112	whole-brain	_	
62-12	10113-10124	correlation	_	
62-13	10125-10129	maps	_	
62-14	10129-10130	,	_	
62-15	10131-10134	and	_	
62-16	10135-10141	Fisher	_	
62-17	10142-10143	Z	_	
62-18	10144-10155	translation	_	
62-19	10156-10159	was	_	
62-20	10160-10170	calculated	_	
62-21	10171-10173	to	_	
62-22	10174-10181	receive	_	
62-23	10182-10193	whole-brain	_	
62-24	10194-10204	functional	_	
62-25	10205-10217	connectivity	_	
62-26	10218-10222	maps	_	
62-27	10223-10224	(	_	
62-28	10224-10227	FCM	_	
62-29	10227-10228	)	_	
62-30	10228-10229	.	_	

#Text=Statistical analysis
#Text=For GMD, ReHo, and FC analyses, one-way ANOVA was initially conducted in the SPM8 to explore whether there were significant differences among the 3 groups: MAP, SCZ, and controls.
63-1	10230-10241	Statistical	_	
63-2	10242-10250	analysis	_	
63-3	10251-10254	For	_	
63-4	10255-10258	GMD	_	
63-5	10258-10259	,	_	
63-6	10260-10264	ReHo	_	
63-7	10264-10265	,	_	
63-8	10266-10269	and	_	
63-9	10270-10272	FC	_	
63-10	10273-10281	analyses	_	
63-11	10281-10282	,	_	
63-12	10283-10290	one-way	_	
63-13	10291-10296	ANOVA	_	
63-14	10297-10300	was	_	
63-15	10301-10310	initially	_	
63-16	10311-10320	conducted	_	
63-17	10321-10323	in	_	
63-18	10324-10327	the	_	
63-19	10328-10332	SPM8	_	
63-20	10333-10335	to	_	
63-21	10336-10343	explore	_	
63-22	10344-10351	whether	_	
63-23	10352-10357	there	_	
63-24	10358-10362	were	_	
63-25	10363-10374	significant	_	
63-26	10375-10386	differences	_	
63-27	10387-10392	among	_	
63-28	10393-10396	the	_	
63-29	10397-10398	3	_	
63-30	10399-10405	groups	_	
63-31	10405-10406	:	_	
63-32	10407-10410	MAP	_	
63-33	10410-10411	,	_	
63-34	10412-10415	SCZ	_	
63-35	10415-10416	,	_	
63-36	10417-10420	and	_	
63-37	10421-10429	controls	_	
63-38	10429-10430	.	_	

#Text=Post hoc analysis was performed in SPSS 18.0 to detect the group differences within ROIs between paired subgroups.
64-1	10431-10435	Post	_	
64-2	10436-10439	hoc	_	
64-3	10440-10448	analysis	_	
64-4	10449-10452	was	_	
64-5	10453-10462	performed	_	
64-6	10463-10465	in	_	
64-7	10466-10470	SPSS	_	
64-8	10471-10475	18.0	_	
64-9	10476-10478	to	_	
64-10	10479-10485	detect	_	
64-11	10486-10489	the	_	
64-12	10490-10495	group	_	
64-13	10496-10507	differences	_	
64-14	10508-10514	within	_	
64-15	10515-10519	ROIs	_	
64-16	10520-10527	between	_	
64-17	10528-10534	paired	_	
64-18	10535-10544	subgroups	_	
64-19	10544-10545	.	_	

#Text=At last, correlation analysis was administrated for 3 parameters and PANSS score in patient groups.
65-1	10546-10548	At	_	
65-2	10549-10553	last	_	
65-3	10553-10554	,	_	
65-4	10555-10566	correlation	_	
65-5	10567-10575	analysis	_	
65-6	10576-10579	was	_	
65-7	10580-10593	administrated	_	
65-8	10594-10597	for	_	
65-9	10598-10599	3	_	
65-10	10600-10610	parameters	_	
65-11	10611-10614	and	_	
65-12	10615-10620	PANSS	_	
65-13	10621-10626	score	_	
65-14	10627-10629	in	_	
65-15	10630-10637	patient	_	
65-16	10638-10644	groups	_	
65-17	10644-10645	.	_	

#Text=The statistical threshold for one-way ANOVA in GMD analysis was set at P<0.001 and clusters size >40.
66-1	10646-10649	The	_	
66-2	10650-10661	statistical	_	
66-3	10662-10671	threshold	_	
66-4	10672-10675	for	_	
66-5	10676-10683	one-way	_	
66-6	10684-10689	ANOVA	_	
66-7	10690-10692	in	_	
66-8	10693-10696	GMD	_	
66-9	10697-10705	analysis	_	
66-10	10706-10709	was	_	
66-11	10710-10713	set	_	
66-12	10714-10716	at	_	
66-13	10717-10718	P	_	
66-14	10718-10719	<	_	
66-15	10719-10724	0.001	_	
66-16	10725-10728	and	_	
66-17	10729-10737	clusters	_	
66-18	10738-10742	size	_	
66-19	10743-10744	>	_	
66-20	10744-10746	40	_	
66-21	10746-10747	.	_	

#Text=For ReHo comparison, the corrected data according with a combination criterion of voxel-wise P value less than 0.001 and cluster sized greater than 6 voxels were regarded as statistically significant, which was the same in the FC analysis.
67-1	10748-10751	For	_	
67-2	10752-10756	ReHo	_	
67-3	10757-10767	comparison	_	
67-4	10767-10768	,	_	
67-5	10769-10772	the	_	
67-6	10773-10782	corrected	_	
67-7	10783-10787	data	_	
67-8	10788-10797	according	_	
67-9	10798-10802	with	_	
67-10	10803-10804	a	_	
67-11	10805-10816	combination	_	
67-12	10817-10826	criterion	_	
67-13	10827-10829	of	_	
67-14	10830-10840	voxel-wise	_	
67-15	10841-10842	P	_	
67-16	10843-10848	value	_	
67-17	10849-10853	less	_	
67-18	10854-10858	than	_	
67-19	10859-10864	0.001	_	
67-20	10865-10868	and	_	
67-21	10869-10876	cluster	_	
67-22	10877-10882	sized	_	
67-23	10883-10890	greater	_	
67-24	10891-10895	than	_	
67-25	10896-10897	6	_	
67-26	10898-10904	voxels	_	
67-27	10905-10909	were	_	
67-28	10910-10918	regarded	_	
67-29	10919-10921	as	_	
67-30	10922-10935	statistically	_	
67-31	10936-10947	significant	_	
67-32	10947-10948	,	_	
67-33	10949-10954	which	_	
67-34	10955-10958	was	_	
67-35	10959-10962	the	_	
67-36	10963-10967	same	_	
67-37	10968-10970	in	_	
67-38	10971-10974	the	_	
67-39	10975-10977	FC	_	
67-40	10978-10986	analysis	_	
67-41	10986-10987	.	_	

